Sigrid K Fey

Aug 29, 2023 | biorxiv.org | Sigrid K Fey |Arafath K. Najumudeen |Catriona A. Ford |Kathryn L. Gilroy

AbstractPancreatic cancer is characterised by the prevalence of oncogenic mutations in KRAS. Previous studies have reported that altered Kras gene dosage drives progression and metastatic incidence in pancreatic cancer. While the role of oncogenic KRAS mutation is well characterised, the relevance of the partnering wild-type KRAS allele in pancreatic cancer is less well understood and controversial.